<?xml version="1.0" encoding="UTF-8"?>
<p>Trivalent IIVs mainly include split‐virus vaccines and subunit vaccines, and are currently approved for use in China. Quadrivalent inactivated influenza vaccines are about to be approved. Other IIVs, such as HD‐IIV and RIV, are not yet available in China. Therefore, herein only recommendations pertaining to TIV administration are provided. TIV should be administered in accordance with the relevant national regulations and vaccine instructions, such as the Regulations on the Administration of Vaccine Circulation (
 <ext-link ext-link-type="uri" xlink:href="http://www.gov.cn/zhengce/content/2016-04/25/content_5067597.htm" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.gov.cn/zhengce/content/2016-04/25/content_5067597.htm</ext-link>) and Vaccination and the Vaccination Practice (
 <ext-link ext-link-type="uri" xlink:href="http://www.gov.cn/yjgl/2005-10/14/content_77713.htm" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.gov.cn/yjgl/2005-10/14/content_77713.htm</ext-link>).
</p>
